Market Research Report
Bromodomain Containing Protein 4 - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||371018|
|Published||Content info||143 Pages
Delivery time: 1-2 business days
|Bromodomain Containing Protein 4 - Pipeline Review, H1 2020|
|Published: February 28, 2020||Content info: 143 Pages||
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2020, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 17 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 4 molecules, respectively.
Report covers products from therapy areas Oncology, Dermatology, Infectious Disease, Immunology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Ovarian Cancer, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atopic Dermatitis (Atopic Eczema), Breast Cancer, Colorectal Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemia, Lung Cancer, Myelodysplastic Syndrome, Neuroblastoma, Non-Hodgkin Lymphoma, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Colon Cancer, Follicular Lymphoma, Hematological Tumor, Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Pancreatic Cancer, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Adenocarcinoma, Advanced Malignancy, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Idiopathic Pulmonary Fibrosis, Inflammation, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Liver Cancer, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Uveal Melanoma and Vascular Dementias.
Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.